Muna Therapeutics discovers and develops therapies that slow or stop devastating neurodegenerative diseases including Alzheimer’s, Frontotemporal Dementia and Parkinson’s. These disorders impact memory, movement, language, behavior and personality resulting in disability and death of millions of patients around the globe.
We focus our groundbreaking science on identifying new medicines to preserve cognition and other brain functions and enhance resilience to neurodegenerative diseases.
Our name reflects this focus: Muna means ‘to remember’ in Old Norse.
More than 200 million patients world-wide are affected by neurodegenerative diseases, representing tremendous unmet medical need.
There are currently no medicines that slow or stop the relentless progression of these diseases. Patients experience difficulties remembering, thinking, understanding and moving, diminishing quality of life for them and their loved ones. Understanding how to slow or stop cognitive impairment, and how to improve resilience to cognitive dysfunction, is the focus of our drug discovery efforts.
We integrate scientific insights from human genetics, bioinformatic analyses of molecular pathways affected in disease, and human cell biology to uncover new ways to repair neuronal function, resolve chronic neuroinflammation, restore neuroprotection and enhance resilience to disease.
We are advancing first-in-class small molecule programs focused on restoring neuron function in patients with progranulin pathway dysfunction that leads to Frontotemporal Dementia, and on resolving neuroinflammation and normalizing microglia function in patients with Alzheimer’s and other neurodegenerative disorders.
Our small molecule drug discovery engine is a powerful combination of high-resolution target structural approaches, AI-driven computational chemistry and cell-based screening in Muna laboratories and with strategic partners.